Roche's CD20xCD3 does­n't beat Gen­mab at ORR, but sets bar for CR da­ta on lym­phoma drug

On its way to po­ten­tial­ly be­com­ing the first to mar­ket with a CD20xCD3 bis­pe­cif­ic for ag­gres­sive lym­phoma, Big Phar­ma’s largest R&D spender has some more da­ta to pad its case with an FDA fil­ing slat­ed for lat­er this year.

Roche dropped some more de­tails from a Phase II ex­pan­sion study of its fixed-du­ra­tion glofi­ta­m­ab, to be pre­sent­ed at next week’s AS­CO an­nu­al meet­ing, in pa­tients with re­lapsed or re­frac­to­ry (R/R) dif­fuse large B-cell lym­phoma (DL­B­CL). The pa­tients had re­ceived a me­di­an of three pri­or ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER